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Mounting evidence suggests that the risk of developing colorectal cancer (CRC) is dramatically increased for patients with chronic
inﬂammatory diseases. For instance, patients with Crohn’s Disease (CD) or Ulcerative Colitis (UC) have a 12–20% increased
risk for developing CRC. Preventive strategies utilizing nontoxic natural compounds that modulate immune responses could
be successful in the suppression of inﬂammation-driven colorectal cancer in high-risk groups. The increase of peroxisome
proliferator-activated receptor-γ (PPAR-γ) expression and its transcriptional activity has been identiﬁed as a target for anti-
inﬂammatoryeﬀorts,andthesuppressionofinﬂammation-drivencoloncancer.PPARγ down-modulatesinﬂammationandelicits
antiproliferative and proapoptotic actions in epithelial cells. All of which may decrease the risk for inﬂammation-induced CRC.
This review will focus on the use of orally active, naturally occurring chemopreventive approaches against inﬂammation-induced
C R Ct h a tt a r g e tP P A R γ and therefore down-modulate inﬂammation.
Copyright © 2009 Ashlee B. Carter et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
The molecular basis for colorectal cancer (CRC) stems from
genomic instability through genetic mutations linked to
oxidative damage from chronic inﬂammation [1, 2]. Dissect-
ing the inﬂammatory networks in the gut and identifying
novel chemopreventive approaches are important because
over 149000 people will be diagnosed with CRC in 2009
in the United States; although there is a trend to a lower
incidencethatprobablycanbeattributedtoextensivescreen-
ing and prevention eﬀorts, almost 50000 people will die of
colon cancer this year [3, 4]. Furthermore, CRC is still the
second leading cause of cancer-related mortality. The most
commonriskfactorsforCRCincludegeneticpredispositions
(adenomatous polyposis coli, hereditary nonpolyposis colon
cancer) and exposure to radiation but intestinal inﬂamma-
tion (ulcerative colitis and Crohn’s disease) also drastically
increase the risk for developing colon cancer especially at
early ages (<30 years of age) [5]. For instance, inﬂammatory
boweldisease(IBD)andothertypesofchronicinﬂammation
increasethe risk fordeveloping more severecolorectalcancer
by 2 or 3 fold [2, 6]. Thus, the role of the immune system
in the development and pathology of cancer is a large and
growingareaofresearch[1].Inaddition,developingeﬀective
chemopreventive interventions is both timely and urgently
needed.
The alimentary tract is a sterile organ at very early stages
of development (i.e., embryonic and fetal phases). However,
after birth, the gastrointestinal mucosa, particularly that
lining the large intestine and terminal ileum, evolves to
become densely colonized by bacteria. Speciﬁcally, from
birth to weaning, successive waves of microorganisms will
colonize the mucosa with a ﬁnal result of 500–1000 species,
which amount to 100 trillion discreet microorganisms,
residing in the large intestine of adult humans [7]. The
number of gut microorganisms is 10 times greater than
the total number of somatic and stem cells [8]. In healthy
individuals, these bacteria contribute to the regulation of
T cell responses [9]. With a few exceptions, the lack of
regulation leads to excessive polarization toward a T helper
1 (Th1) phenotype and initiation of IBD. The cellular
interactions between T cells and antigen-presenting cells2 PPAR Research
occurring in the gut mucosa and draining lymph nodes
are tightly regulated to prevent excessive immune responses
to foods and the gut microﬂora, whereas a defect in
down-regulation of the immune responses predominates
in individuals with IBD. The distribution and function of
lamina proprial macrophages and T cells in the gut mucosa
are important determinants of the extent and severity of the
inﬂammatory process, and thus, represent targets for anti-
inﬂammatory compounds. Bioactive food ingredients such
as n-3 polyunsaturated fatty acids (PUFAs) and conjugated
linoleic acid (CLA) are well recognized to suppress colonic
inﬂammation and decrease the risk of colorectal cancer [10].
However, the limited understanding about their mechanisms
of anti-inﬂammatory action has halted further progress in
the development of nutrition-based approaches for prevent-
ing this devastating and widespread disease.
Many of the anti-inﬂammatory bioactive food ingre-
dients and nutraceuticals elicit its actions through nuclear
receptors, a broad class of transcription factors which
regulate the expression of genes [11]. The peroxisome
proliferator-activated receptors (PPARs), which make up
a fatty acid binding subfamily of nuclear receptors, are
involved regulating immune responses and therefore are
potential therapeutic targets for CRC [12]. Nuclear receptors
are common pharmaceutical targets for diabetes, IBD,
endotoxemia. Of note, about 13% of all FDA-approved
drugs target nuclear receptors [13]. Thus, they oﬀer a great
potential as targets for novel chemopreventive agents against
both gut inﬂammation and inﬂammation-induced CRC.
2.Signiﬁcanceof CRC
Colorectalcancerisoneofthemostprevalenttypesofcancer,
secondonlytolungcancer[14].In2004,over35%ofallmen
and women in the United States diagnosed with CRC died.
The risk of colorectal cancer in the general population is less
than 7%, though chronic inﬂammation including ulcerative
colitis (UC) and Crohn’s disease (CD)—the two clinical
manifestations of IBD—can increase the risk of colorectal
cancer. More speciﬁcally, the risk of developing colorectal
cancer for an ulcerative colitis patient is estimated to be 2%
after 10 years, 8% after 20 years, and 18% after 30 years of
disease onset [15].
DemographicsisanotherfactorrelatedtoCRC,although
not as strong as inﬂammation. Evidence suggests that
ethnicity, gender, and geography all play a role. For instance,
African American males over 50 living in the Western world
are statistically at the highest risk for CRC [16]. Overall,
inﬂammation emerges as the major factor for developing
CRC. The consequences of CRC can be signiﬁcant as the
main therapies include colon removal which can lower
dramatically a patient’s quality of life, or lifelong surveillance
including regular colonoscopies and medications, some of
which have signiﬁcant side eﬀects [2]. In addition, in
contrast to the more limited cost of chemoprevention, the
cost of palliative treatment can represent a major burden
for many CRC patients, with frequent hospital visits and
expensive medications. Over 1.8 billion dollars are spent in
m e d i c a lc a r ef o rI B Dp a t i e n t sp e ry e a r[ 16]. All of which
could be minimized with more eﬀective chemopreventive
approaches.
3. The Role of the Mucosal Immune
System in CRC
The mucosal immune system consists of cells and organs
associated with body surfaces directly exposed to the
environment, including lymphoid tissues associated with
the lachrymal, salivary, gastrointestinal, respiratory and
urogenital tracts as well as the lactating breasts [17]. The
mucosal immune system is divided into inductive sites,
where the immune responses are initiated or induced
(antigen presentation to T cells) and eﬀector sites, where
responses are elicited (e.g., cytokine production, pathogen
destruction).
Interestingly, about 70% of the immune system is
localized in the gastrointestinal tract. Thus, understanding
its architecture, functions, and how to favorable manipulate
them is paramount for a rational design of chemopreven-
tive approaches against both gastrointestinal inﬂammation
and CRC. The gut associated lymphoid tissue (GALT)
includes tonsils (lingual tonsils or Waldeyer’s ring), ade-
noids (nasopharyngeal tonsils), appendix and specialized
structures called Peyer’s Patches, draining lymph nodes (i.e.,
mesenteric lymph nodes) in inductive sites and diﬀuse
lymphoid tissue including intraepithelial lymphocytes and
lamina propria cells (i.e., T cells, B cells, plasma cells,
macrophages, dendritic cells, eosinophils, and mast cells)
and isolated follicles in eﬀector sites. Alterations in the
GALT are well recognized to be an important mechanism
underlying impaired host defense in CRC patients. Diet
plays an important role in shaping the GALT as the
lack of enteral delivery of nutrients decreases the num-
bers of T cells in the intraepithelial spaces and lamina
propria of colorectal cancer patients [18]. In addition,
the gastrointestinal tract is in very close proximity with
the intraabdominal white adipose tissue (WAT) which in
obese and overweight individuals is populated by large
numbers of inﬂammatory macrophages [19]. Thus, the
cross-talk between the GALT and WAT may play a role
in shaping inﬂammatory responses that lead to CRC. In
this regard, Crohn et al. in 1932 published a landmark
paper characterizing for the ﬁrst time Crohn’s disease [20].
In this study, changes in the appearance in mesenteric
adipose tissue were reported to be a key characteristic of
the disease. In line with those early ﬁndings, we have
recently found that macrophage inﬁltration into the intra-
abdominalfatworsenstheseverityofexperimentalIBD[21].
Epidemiologicalevidencesuggestsalinkbetweenobesityand
human CRC [22]. While the speciﬁc mechanisms underlying
this link remain unknown, obesity-related inﬂammation
represents a plausible explanation for this increased risk.
The better understanding of the relationship between GALT
and WAT may uncover some novel insights on mechanisms
of carcinogensis and shed new light on possible preventive
approaches.PPAR Research 3
The immune modulatory activities that aid in CRC
chemoprevention by suppressing inﬂammation diﬀer from
the type of immune modulation after carcinogenesis has
already occurred. Diﬀerent modulatory agents should be
sought for before and after carcinogenesis in order to
heighten antitumor immune responses (i.e., T helper 1 and
CD8+ T cell-mediated cytolytic responses) and to achieve
optimal therapeutic eﬃcacy. The mucosal immune system
will play a crucial role in both phases of the disease.
Interestingly, PPARγ is expressed by all cell types that play
a major role in the pathogenesis of CRC, including epithelial
cells, T cells, and macrophages [23]. Therefore their function
can theoretically be modulated by this nuclear receptor.
4. Inﬂammation-InducedCRC
It is estimated that approximately 15% of deaths in patients
with CD and UC can be attributed to inﬂammation-
induced CRC. The risk of developing CRC for CD and
UC patients increases yearly, eventually reaching 12–20%
increased risk after living with disease for 30 years [24].
Markers of inﬂammation like C reactive protein (CRP)
whose synthesis occurs in hepatocytes and is induced by IL-6
and TNF-α in the serum have even been used as predictors
of disease severity in advanced stages of CRC [16, 25].
While the exact mechanism for this elevated risk is still
unknown, recent studies have been investigating whether the
marked reduction in levels of the nuclear receptor PPARγ in
colons of UC patients may play a role in their increased
susceptibility to developing colorectal cancer [26]. The exact
mechanisms by which inﬂammation leads to CRC are slowly
being elucidated.
The transcription factor nuclear factor kappa B (NF-
κB), which is found at the crossroads of many inﬂammatory
pathways, has also been linked to tissue repair [27]. Aberrant
NF-κB signaling has been proposed to be one of the
mechanisms by which chronic inﬂammation leads to cancer
[28]. In a murine model of intestinal cancer, adenomatous
polyposis coli (APC)min/+ mice, it was shown that the TLRs
andIL-1R,throughtheadaptorMyD88,controlthesignaling
of many genes which modify tumorigenesis in the intestine,
including the NF-κB-mediated genes IL-6 and IL-1β [29].
Loss-of-function studies demonstrated that MyD88-induced
IL-6 was necessary for colon carcinogenesis [30].
Another upstream regulator of NF-κB, tumor necrosis
factor alpha (TNF-α), also plays a role in the development of
IBD and CRC. TNF-α is a pro-inﬂammatory cytokine which
activates NF-κB as a positive autocrine feedback signal.
Once activated, NF-κB induces further production of TNF-
α and other pro-inﬂammatory mediators [31]. The positive
feedback loop between TNF-α and NF-κB may lead to the
overactivation of the NF-κB tissue repair pathways, which in
turn leads to tumorigenesis. Blockade of NF-κBd r a m a t i c a l l y
reduced tumor incidence by 75% in mice with DSS colitis
[32]. Popivanova et al. more recently showed that treatment
of DSS-challenged mice with a TNF-α inhibitor also reduces
tumor incidence [33]. High levels of circulating TNF-α in
plasma are associated with colorectal adenomas [34], further
conﬁrming the link between systemic inﬂammation and
CRC.
One of the hallmarks of cancer cells is an uncontrolled
growth and supported by a metabolic shift from aerobic
to anaerobic metabolism [35]. This leads to an increased
production of reactive oxygen species (ROS) in the electron
transport chain. A state of chronic inﬂammation may also
increase production of ROS as cytokines in inﬂammatory
sites recruit macrophages and neutrophils which produce
ROS. The ROS damage DNA which leads to mutations
and the development of cancer [36]. ROS are also involved
in pathways which progress tumor growth by increas-
ing the production of interleukin 8 (IL-8) and inducible
nitric oxide (iNOS), and inducing the secretion of matrix
metalloprotease-1 (MMP-1) [37]. This illustrates an inter-
action between dysregulated host responses characterized by
excessive inﬂammation resulting in genotype changes (i.e.,
mutations) that will in turn lead to CRC.
5. Role of PPARγ inRegulating
Inﬂammation-InducedCRC
The PPARs are a subfamily of nuclear hormone receptors
whichrecognizeawiderangeofligands,thenheterodimerize
with retinoid X receptor (RXR), and regulate expression of
responsive genes. They also antagonize the activity of tran-
scription factors, involved in inﬂammation and immunity
such as NF-κB, activator protein-1 (AP-1), nuclear factor of
a c t i v a t e dTc e l l s( N F A T ) ,a n dS T A T s[ 38]. Three diﬀerent
isotypes of PPARs, each of which represents a therapeutic
target, have so far been identiﬁed: PPARα,P P A R δ,a n d
PPARγ [39]. Of the three subtypes, PPARγ,i np a r t i c u l a r ,
represents a potential therapeutic target for CRC and IBD
chemoprevention. However, the apparent ability of PPARγ
to promote diﬀerentiation and maturation of epithelial cells
hasalsoledtostudiesofitspotentialroleinthecauseofCRC.
Animal studies suggest both pro- and anticancer properties
in the colon [40–42], though the bulk of studies point to
PPARγ ligands as chemopreventative agents [43].
PPARγ is found in monocytes, macrophages, T cells,
dendritic cells, skeletal muscle, adipocytes, and gastrointesti-
nal epithelium and is involved in wide range of processes
including the regulation of lipid and glucose homeostasis,
inﬂammation, and adipocyte diﬀerentiation [38, 44]. One
way by which PPARγ acts in an anti-inﬂammatory capacity
is through the inhibition of NF-κB activity. More speciﬁcally,
PPARγ can interact directly with the NF-κB subunits p50
and p65 [45]. In fact PPARγ has been shown to antagonize
the NF-κB activities through several mechanisms. A non-
pathogenic bacterium present in the human gut, B. thetaio-
taomicron, acts in an anti-inﬂammatory capacity in Caco-2
cells by stimulating PPARγ t oa c ta san u c l e a r - c y t o p l a s m i c
shuttle for the p65 subunit of NF-κB. PPARγ binds to the
p65 subunit and prevents NF-κB transcriptional regulation
by exporting it from the nucleus [46]. In macrophages,
sumoylation of PPARγ ligand-binding domain prevents the
removal of the nuclear receptor corepressor (NCoR)/histone
deacetylase-3 (HDAC3) complex from the promoters of4 PPAR Research
CD UC
Chronic inflammation
TLR, IL-1R ROS
MyD88 DNA damage
Tumor growth
Cancer
IL-8, iNOS, MMP-1  PPARγ
TNF-α NF-κB
IL-6, IL-1β
PPARγ
Figure 1: Chronic inﬂammation activates pathways leading to cancer. Chronic inﬂammation stemming from ulcerative colitis (UC) and
Crohn’s disease (CD), the two clinical manifestations of inﬂammatory bowel disease, activates nuclear factor-κB( N F - κB) downstream of
MyD88 through the TLR and IL-1R. In turn, NF-κB activation increases the expression of pro-inﬂammatory cytokines IL-6 and IL-1β.
TNF-α also activates NF-κB which, in turn, increases the expression of TNF-α, leading to a positive feedback loop between TNF-α and
NF-κB. Chronic inﬂammation also leads to the production of ROS which can damage DNA which can cause mutations responsible for
tumorigenesis. ROS also cause the production of IL-8, iNOS, and MMP-1, which promote tumor growth. On the other hand, activation of
PPARγ can block carcinogenesis at two levels: (1) by antagonizing NF-κB activity and (2) by suppressing IL-8 and iNOS expression.
proinﬂammatory genes and, therefore, blocks NF-κB[ 47,
48]. Stimulation of colonic epithelial cells with PPARγ
ligands prevents the immune-induced degradation of IκB,
anchoring NF-κB in the cytosol [49]. Overall, the inhibition
of NF-κB in response to the activity of PPARγ ligands atten-
uates the expression of various cytokines and inﬂammatory
cells in colonic epithelial cells such as IL-1beta, COX-2, IL-6
IL-8, TNF-α,I F N - γ, and iNOS [48–51].
Increased expression of PPARγ in human colorectal
cancer cell lines treated with troglitazone, a PPARγ agonist,
is associated with increased diﬀerentiation [52]. This eﬀect
may exert itself due to the interaction of PPARγ with the
coactivator protein, Hic5, expressed in colonic epithelial
cells. The expression of both Hic5 and PPARγ is down-
regulated in tumors. This interaction mediates induction of
gut epithelial diﬀerentiation markers such as keratin 20 in
gastrointestinal cells [53].
Pioglitazone, a synthetic agonist for PPARγ, increases
protein expression of caspase-3, a pro-apoptotic protein, and
decreases protein expression of apoptotic inhibitory proteins
Bcl-2, COX-2, and XIAP in retinoblastoma protein (RB)-
deﬁcient human CRC cells (SNU-C4 and SNU-C2A) [54].
These results have been demonstrated with several CRC cell
lines using a number of PPARγ agonists [55–58]. However,
a limited number of mechanistic studies in inﬂammation-
induced CRC are availableusing naturallyoccurring agonists
of PPARγ.
6. PotentialUseofNaturallyOccurringAgonists
of PPARγ for CRC Chemoprevention
A number of studies have examined the use of naturally
occurring compounds for the prevention and treatment of
inﬂammatory diseases and several types of cancer (Table 1).
These naturally occurring compounds represent naturally
occurring agonists of PPARγ and/or potential therapies for
inﬂammation induced-CRC. However, only a few have
shown eﬃcacy in the prevention or treatment of CRC.
Among those are n-3 polyunsaturated fatty acids (PUFAs),
which are known ligands or activators for PPARs. An
active role for protein syndecan-1, which is regulated by
PUFAs and a PPARγ molecular target, has recently been
identiﬁed in causing apoptosis in both prostate and breast
cancer cells [83]. There is also some evidence to suggests
docosahexaenoic acid (DHA), one of the PUFAs, is impor-
tant in cellular apoptosis and cell cycle arrest in colorectal
cancer. DHA and eicosapentaenoic acid (EPA) work at the
molecular level through signaling pathways putting stress on
proliferating cells and ultimately causing changes in gene
expression of cancer cell lines [84]. DHA has generated
promising results in animal studies with transplantable
or chemically induced tumor. Success in some preclinical
animal studies has led to clinical trials, many of which are
ongoing, which use n-3 PUFAs as a nutritional supplement
to reduce inﬂammation and modulate immune response
[85]. Previously, we have demonstrated that dietary supple-
mentation with conjugated linoleic acid (CLA) upregulated
colonic expression of PPARγ and downregulated colonic
expression of TNF-α and inﬂammatory lesions in DSS-
challenged pigs [86]. In DSS-challenged mice, immune and
epithelial cellPPARγ wasrequired fortheanti-inﬂammatory
eﬃcacy of CLA [75].
Another naturally occurring agent which shows promise
in CRC is γ-Tocopherol—a vitamin that decreases COX-2
activity and nitric oxide (NO) expression [87]. The chemo-
protective eﬀect of γ-Tocopherol may also occur through an
upregulation PPARγ as treatment of human colon cancerPPAR Research 5
Table 1: Natural compounds with therapeutic action against inﬂammation.
Compound name Implications Disease target Study type Molecular targets
Resveratrol (found in red wine, white
hellebore) [59, 60] Prevention
Skin cancer, colon cancer,
diabetes,
neurodegeneration
Cell culture,
rodent, phase I
clinical trial
Inhibition or reduction of
COX-1 and COX-2, ROS
Beta-carotene (terpenoid found in yellow
and orange fruits and vegetables) [61] Prevention Inﬂammation, high
cholesterol Mouse, ferret ROS
Curcumin (spice derived from turmeric)
[62, 63]
Prevention,
therapy
Pancreatic cancer,
myelodysplastic
syndromes, colon cancer,
psoriasis, inﬂammation
Cell culture, rat,
clinical trials
Inhibits, COX activities, ROS,
inhibits production of many
pro-inﬂammatory cytokines
(IL-8, MCP-1, TNF-α)
Folic acid (leafy vegetables and grain
product) [64] Prevention Rectal health, pancreatic
and CRCs
Cell
culture/rodent
Involved in function,
synthesis, and repair of DNA
in cell cycle
Tocopherols (form of vitamin E found in
oils and wheat germ) [65]
Treatment
(supplement
to anticancer
drugs)
Prostate and lung cancers,
CRC, and melanoma Cell culture/rat
Mitochondrial interactions
with compounds leading to
apoptosis, upstream
inhibition of NF-κB
Omega-3 polyunsaturated fatty acids
(PUFAs; found in grains, ﬁsh, and some
oils) [66]
Treatment IBD
Rat, mouse,
human cancer
cells
Cell cycle arrest and apoptosis
through inhibition of the
PI3-kinase signaling pathway,
PPARγ activation
Vitamin D or calcitrol (plant sources,
fungi, dairy, and ﬁsh) [67, 68] Treatment
Rheumatoid arthritis,
dermatological conditions,
osteoporosis, prostate,
colon and breast cancers
Mouse, human
clinical trial
Phase G0/G1 cell cycle arrest,
regulation of cell cycle
proteins, reduction of Akt and
Erk which are cell survival
markers
Calcium (dairy, nuts, seeds, soy, plants
such as kelp and seaweed) [67]
Treatment/
prevention
Rheumatoid arthritis,
dermatological conditions,
osteoporosis, prostate,
colon cancer, breast
cancers and diabetes
Cell culture,
mouse, human
clinical trial
Balances cellular proliferation
in the colon by inducing
apoptosis
Dietary ﬁber (plant products, beans, root
vegetables) [69, 70] Prevention IBD, CRC
Cell culture,
human clinical
trial
Butyrate, product of dietary
ﬁber functions best with
retenoids to inhibit histone
deacetylase, butyrate regulates
colonic epithelial homeostasis
Probiotics (fermented dairy) [71, 72] Treatment/
prevention IBD Human clinical
trial
Known mechanisms or targets
are intestinal microﬂora,
chemical balance, binds to
carcinogens, production of
short-chain FAs and
anti-carcinogens
Prebiotics and synbiotics
(oligosaccharides, garlic, onion, artichoke,
and asparagus) [72, 73]
Treatment Colitis, inﬂammation,
cancer
Rats, clinical
trial
Production of short-chain
FAs, induce apoptosis of
damaged cells, enhances
activity of NK cells
Quercetin (a ﬂavonoid found in
cranberries and onions) [74] Prevention
Breast, lung, skin, and
colon cancers, heart
disease
Cell culture,
rodent
ROS, a proposed
aryl-hydrocarbon receptor,
suppresses pro-inﬂammatory
mediators
CLA (dairy, meat) [75] Prevention IBD Mouse, pigs
Enhances the immune
function, activates PPARγ,
downregulates
pro-inﬂammatory cytokines
through NF-κB6 PPAR Research
Table 1: Continued.
Compound name Implications Disease target Study type Molecular targets
Ginseng (root of the panax plant in the
family araliaceae)[ 76]
Prevention/
enhancement
of current
treatment
Colon cancer Cell culture,
mouse
Suppresses TNF-α and NF-κB
signaling decreasing
inﬂammation. Also targets
movement and angiogenesis
of carcinoma cells
Turmeric extract (curry, curumin) [77] Treatment Arthritis, inﬂammation,
cardiovascular disease Rodent
Inﬂammation, angiogensis,
eliminates free redicals and
ROS, suppresses TNF-α
Phytoestrogen (soy products, whole
grains) [78, 79] Prevention CRC, breast cancer,
prostate cancer
Rat, clinical
trial
Induction of apoptosis and
inhibition of tyrosine kinases,
regulates some
pro-inﬂammatory cytokines
(IL-6) hormones which
induce cancer
Kaempferol (ﬂavonoid in apples, onions,
broccoli, and citrus fruits) [80]
Treatment/
prevention
Obesity and type II
diabetes, cardiovascular
diseases,
neurodegenerative
diseases, cancer
Cell culture
Upregulates TNF-related
apoptosis-inducing ligand
(TRAIL) receptors, sensitizes
cancer cells to
anti-carcinogenic compounds
and pathways
Green tea phenols (tea leaves) [81] Treatment Gastric cancer and H.
Pylori infections
Cell culture,
mouse
Reduce ROS, gluthione
metabolism, activates
apoptotic markers and tightly
regulates the cell-cycle
Blueberry Extracts (fruit from the shrub,
vaccinium cyanococcus)[ 82] Treatment Cancer, inﬂammation Cell culture,
mouse
Inhibit growth, stimulate
apoptosis
cells (SW480 cells) with both 5 and 10μM concentrations of
γ-Tocopherol resulted in an increase of both PPARγ mRNA
and protein expression [88].
T h er o l eo fd i e ti nc o l o r e c t a lc a n c e rm a yb ee v e nm o r e
important than in other cancers due to the direct eﬀect
compounds have with the gut. This local eﬀect has been
shown to be critical for curcumin—a compound with neg-
ligible distribution outside the gut [89]. Broadly, methods
of direct inhibition through nutraceuticals include reducing
damage to DNA by neutralizing carcinogens, cytotoxicity
or apoptosis of tumor cells, antiangiogenesis, and acting
as anti-inﬂammatory agents [90]. In line with the concept
of personalized medicine, some physicians recommend that
people with a family history of cancers, or previously
detected dysplasia or microtumors consume nutraceuticals
ﬁrst and foremost in the form of food and also in the form of
multivitamins to decrease the risk of cancer [90]. However,
the limited understanding of the mechanisms of action
underlying the eﬀects of botanicals, vitamins, and fatty acids
has slowed down the rational development of preventive
and therapeutic approaches against inﬂammation-induced
CRC.
7. Conclusions andFutureDirections
People with CD or UC are predisposed to developing CRC,
an outcome that depends on the extent and duration of
chronic inﬂammation, which in turn is dependent on NF-
κB and ROS activity [6]( Figure 1). The key to maintaining
homeostasis in the gut entails both downregulating inﬂam-
mation as a chemopreventative method and promoting
epithelial cell apoptosis and anti-tumor immune responses
after the onset of cancer. As such, it is reasonable to
suspect that introducing bioactive food ingredients which
modulate NF-κB or ROS pathways could be used to regulate
inﬂammation before the onset of cancer. PPARγ ligands have
consistently acted as modulators and suppressors of NF-κB
activity [45–48, 91].
Thiazolidinediones (TZDs) are a well-known class of
diabetes medication which acts as PPARγ ligands. TZDs
also suppress tumorigenesis in several types of cancers,
including colon cancer [92]. Therefore, the identiﬁcation of
novel, naturally occurring PPARγ ligands may represent a
promising route of CRC chemoprevention.
Thereisalsostrongpotentialfortheuseofthesebioactive
compounds in conjunction with current treatments as this
approach has already been shown to have positive results in
cancer treatment [43].
The therapeutic eﬀects of dietary CLA, and PUFAs
through the activation of PPARγ have already been summa-
rized. Natural compounds for the treatment of CRC through
PPARγ have the potential to modulate the immune response
and to be safe, easily accessible, and cost-eﬀective.
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